For in-vitro research use only. Not for human consumption.
Retatrutide
Retatrutide differs from earlier metabolic peptides by simultaneously engaging three distinct G-protein-coupled receptors that regulate energy intake, energy expenditure, and glucose homeostasis. Semaglutide targets only GLP-1; tirzepatide targets GIP and GLP-1; retatrutide adds glucagon receptor agonism as the third axis, contributing to increased energy expenditure in published preclinical work.
Retatrutide definition
Retatrutide differs from earlier metabolic peptides by simultaneously engaging three distinct G-protein-coupled receptors that regulate energy intake, energy expenditure, and glucose homeostasis. Semaglutide targets only GLP-1; tirzepatide targets GIP and GLP-1; retatrutide adds glucagon receptor agonism as the third axis, contributing to increased energy expenditure in published preclinical work.
No sequence is listed in the current catalog record for this product.
- CAS
- 2381089-83-2
- MW
- 4731.33 Da
- Sequence
- Not listed
- Half-life
- Discussed in research notes
- Formula
- C221H342N46O68
- Purity
- 99.49%
- Form
- Lyophilized powder
- Class
- GIP/GLP-1/Glucagon Triple Receptor Agonist
Reconstitution calculator
Estimate vial concentration and aliquot volume from the selected vial mass, solvent volume, and target research amount.
Calculations are for lab planning only and do not replace the product COA, protocol requirements, or qualified professional review. Confirm solvent compatibility before use.
Compound details.
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4731.33 Da
- Molecular Formula
- C₂₂₁H₃₄₂N₄₆O₆₈
- Class
- GIP/GLP-1/Glucagon Triple Receptor Agonist
- Purity
- ≥99% purity
- Physical Form
- Lyophilized powder
- Storage
- Store at -20°C (long term). Refrigerate after reconstitution.
Research context.
Retatrutide is one of the most extensively studied incretin-family peptides published in the past five years. The phase 2 obesity trial reported by Jastreboff and colleagues in the New England Journal of Medicine demonstrated dose-dependent body weight reductions of up to 24.2% at 48 weeks in the 12 mg cohort, alongside improvements in glycemic control, blood pressure, and lipid markers. Earlier discovery and pharmacology data from Coskun et al. (Cell Metabolism, 2022) characterized the receptor binding profile and proof-of-concept activity in animal models.
Verification standard.
Every Nexus Laboratory batch ships with a Certificate of Analysis documenting HPLC purity (target ≥98%), mass spectrometry identity (expected versus observed mass), and endotoxin screening — verified by third-party laboratory testing and publicly archived. Review Nexus lab verification.
Retatrutide is part of the Nexus GLP-1 & Metabolic catalog. GLP-1, amylin, and multi-agonist metabolic research peptides. Each listed variant is priced from the consolidated Nexus catalog and intended for qualified research use only.
TODO-COPY: replace with real compound-specific narrative.
The chemistry.
Static molecular fallback shown because this catalog record does not include a sequence suitable for the amino-acid viewer.
Storage: Store at -20°C (long term). Refrigerate after reconstitution.
HPLC trace preview.
Related research compounds
Same category, mechanism overlap, and common research stack pairings.
Retatrutide research FAQ.
What is Retatrutide used for in research?
Retatrutide is supplied for controlled in-vitro research workflows in the GLP-1 & Metabolic category. It is not labeled for human or veterinary use.
Is Retatrutide HPLC verified?
Retatrutide is listed with Nexus lab verification. Current catalog records show 99.49% purity context where batch COA data is available.
Which Retatrutide sizes are available?
Current Nexus variants include 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg.
Does Retatrutide include a COA?
Yes. The current Nexus record links Retatrutide to batch NEX-RETATRUTIDE-2026-0073.